Beam Global Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Beam Global (BEEM) on March 4, 2022. The report details the completion of a strategic acquisition of All Cell Technologies, LLC ("All Cell"), a move intended to expand Beam's asset base and business operations.
Key Financial Metrics and Transaction Details
The filing does not provide consolidated revenue, profit, cash flow, or margin data for Beam Global. The financial specifics relate solely to the acquisition consideration:
- Equity Consideration: 1,055,000 shares of Beam Common Stock issued to All Cell.
- Cash Consideration: $911,711 paid for net working capital, primarily inventory.
- Debt and Liquidity: The filing text does not provide clear values for the company's current debt levels or liquidity position.
Material Changes and Earnout Structure
The primary material change is the acquisition of All Cell's assets and business. The transaction includes a significant contingent "Earnout Consideration" based on future performance:
- 2022 Milestone: Two times the amount of All Cell revenue and contracted backlog exceeding $7.5 million.
- 2023 Milestone: Two times the amount of 2023 revenue exceeding the greater of $13.5 million or 135% of 2022 cumulative revenue.
- Cap: The total Earnout Consideration is capped at $20 million. Revenues exceeding $20 million in 2023 are not eligible for additional earnout shares.
Guidance, Risks, and Unusual Items
Financial Statements: Beam intends to file the required financial statements of the acquired business and pro forma financial information via an amendment to this Form 8-K within 71 days of the initial filing date. These documents are not included in this report.
Securities Issuance: The shares issued to All Cell were sold pursuant to an exemption under Section 4(a)(2) of the Securities Act and Rule 506(b), meaning they were not registered under the Securities Act of 1933.
Risks: The filing notes that the description of the merger is qualified by reference to the full Asset Purchase Agreement. Future financial impact depends on All Cell meeting the specified revenue milestones.
Key Facts for Investor Verification
- Verify the exact number of shares issued (1,055,000) and the dilution impact on existing shareholders.
- Monitor the upcoming amendment to this 8-K (due within 71 days) for the pro forma financial information and All Cell's historical financial statements.
- Track All Cell's 2022 revenue and backlog to determine the initial earnout payout eligibility.
- Review the full Asset Purchase Agreement (Exhibit 2.1) for detailed terms regarding the net working capital adjustment and earnout mechanics.